DAKAR, SENEGAL — In a monumental stride for African health sovereignty, Senegal has successfully launched a locally manufactured sickle cell drug that more than halves the cost of life-saving treatment. The medication is already poised to change the landscape of healthcare for millions across the continent.
Manufactured by Dakar-based Teranga Pharma, DREPAF (hydroxyurea) was launched in November 2025, marking the very first time the standard treatment for sickle cell disease has been manufactured locally on the African continent.
The economic shift is immediate and life-changing: a 500-milligram capsule for adults now costs just 98 CFA francs, a drastic reduction from the 203 CFA francs patients previously had to pay for imported equivalents from France or India. A 100-milligram dose has also been made available specifically for children, delivering the exact same molecule at a fraction of the original price.
The Staggering Reality of Sickle Cell in Africa
The global burden of sickle cell disease is overwhelmingly concentrated in Africa, which accounts for roughly 80% of the world’s cases. Yet, due to fragile supply chains and exorbitant pricing set by foreign pharmaceutical companies, access to medication has remained alarmingly low. In Senegal alone, prior to DREPAF’s launch, only 17% of patients who desperately needed the drug could actually get it.
Medical experts are hailing the drug’s local production as a game-changer. Hydroxyurea is not just a painkiller; it is a vital, disease-modifying therapy that induces fetal hemoglobin, reduces excruciating vaso-occlusive crises, cuts hospitalizations, and ultimately extends life expectancy.
As veteran primary care physician Dr. Njide Okonjo-Udochi noted in response to the breakthrough: “Hydroxyurea is not a nice-to-have… When cost or supply keeps it out of a patient’s hands, we are not managing the disease, we are watching it manage the patient. A regional manufacturing model that drives prices down and keeps supply chains closer to the patients who need them is not a symbolic win. It is, quite literally, a lifeline.”
A Crack in the Wall of Import Dependence
For decades, the continent has relied heavily on imported medications: malaria drugs from India, HIV treatments from the US, and sickle cell pills from Europe. Every shipment required foreign currency, foreign permission, and foreign pricing.
Teranga Pharma’s initiative shifts the narrative from foreign aid and importation to pure manufacturing power. A Senegalese lab hired Senegalese chemists, procured raw materials, ran rigorous quality control, and produced a tablet that meets the exact same global standards as its imported counterparts. The difference? The jobs stay in Dakar, the profits stay in Dakar, and the price drops low enough that a rural farmer in Kaolack can afford what a banker in Paris takes for granted. WOW!
Looking Ahead: A Pan-African Vision
Teranga Pharma is not stopping at Senegal’s borders. DREPAF is actively changing the math for neighboring nations. Burkina Faso, Guinea, and the Ivory Coast are already collaborating with the manufacturer to bring the drug across their borders, while the Democratic Republic of Congo, Gabon, and Cameroon have submitted formal requests.
The company has set an ambitious goal: to supply all of sub-Saharan Africa with affordable sickle cell medication by 2030.
While a single drug cannot single-handedly fix infrastructural healthcare challenges or build roads to rural clinics, it represents a massive paradigm shift. As Dr. Zainab Suleiman profoundly summarized the achievement: “It proves that Africa can make what Africa needs, and sell it to Africa at an African price. That is the point. That is the win.” Win win scenario!
For more exclusive updates on healthcare innovations, regional development, and stories shaping our world, keep it locked to ABT NEWS at www.abtnews.net.
By
